NMS · Financial Statements

Inhibrx Biosciences, Inc. (INBX) Financial Statements

$93.38 NMS: INBX Market Cap $1.37B

Inhibrx Biosciences, Inc. most recently reported annual revenue of $1.0M, a net loss of $140.0M. Revenue declined at an average annual rate of 40.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Inhibrx Biosciences, Inc.: Revenue fell from $7.0M in 2016 to $1.0M in 2025, a change of -85.7% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -182.2% to -10386.5%, a shift of -10204.4 percentage points; the most recent year shows a net loss of $140.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$7.0M$8.0M$9.0M$9.0M$13.0M$7.0M$2.0M$2.0M$0$1.0M
Operating Expenses$19.0M$28.0M$38.0M$50.0M$80.0M$84.0M$131.0M$221.0M$332.0M$136.0M
Operating Profit$-12.0M$-20.0M$-30.0M$-41.0M$-67.0M$-77.0M$-129.0M$-219.0M$-331.0M$-135.0M
Operating Margin-182.2%-235.1%-343.4%-450.4%-526.6%-1076.1%-5890.4%-12178.9%-165724.0%-10386.5%
Other Income$-1.0M$-2.0M$-1.0M$-10.0M$3.0M$-5.0M$-16.0M$-21.0M$2.0B$-5.0M
Interest$0$2.0M$1.0M$6.0M$11.0M$5.0M$16.0M$32.0M$13.0M$12.0M
Depreciation$0$0$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M$2.0M
Profit Before Tax$-13.0M$-22.0M$-31.0M$-51.0M$-76.0M$-82.0M$-145.0M$-240.0M$1.7B$-140.0M
Tax$35.8M$-1.1M$-310,000$-1.8M$0$0$0$0$0$0
Net Profit$-8.0M$-19.0M$-31.0M$-51.0M$-76.0M$-82.0M$-145.0M$-241.0M$1.7B$-140.0M
EPS$-0.23$-0.68$-1.15$-1.41$0.00$-2.15$-3.62$-5.12$116.58$-9.04
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$2.0M$0$0$0$0$0$1.0M$0$0$0$0
Operating Expenses$46.0M$90.0M$74.0M$161.0M$47.0M$50.0M$43.0M$29.0M$34.0M$31.0M$31.0M$32.0M
Operating Profit$-46.0M$-88.0M$-74.0M$-161.0M$-47.0M$-50.0M$-43.0M$-27.0M$-34.0M$-31.0M$-31.0M$-32.0M
Operating Margin-38510.1%-5403.2%0.0%-160898.0%0.0%-49928.0%0.0%-2106.8%0.0%0.0%0.0%0.0%
Interest$8.0M$8.0M$8.0M$5.0M$0$0$3.0M$3.0M$3.0M$3.0M$4.0M$6.0M
Profit Before Tax$-52.0M$-94.0M$-79.0M$1.9B$-44.0M$-48.0M$-43.0M$-29.0M$-35.0M$-33.0M$-33.0M$-37.0M
Tax$0$0$0$0$0$0$0$-10,000$0$0$0$-10,000
Net Profit$-52.0M$-94.0M$-79.0M$1.9B$-44.0M$-48.0M$-43.0M$-29.0M$-35.0M$-33.0M$-33.0M$-37.0M
EPS$-1.10$-1.73$-1.44$125.48$-2.84$-3.31$-2.80$-1.85$-2.28$-2.11$-2.15$-2.34

Over the 10 years reported for Inhibrx Biosciences, Inc., borrowings increased from $19.0M in 2016 to $107.0M in 2025, cash stood at $124.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.91 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$21.0M$17.0M$10.0M$26.0M$144.0M$150.0M$291.0M$308.0M$181.0M$146.0M
Current Assets$20.0M$15.0M$6.0M$16.0M$132.0M$139.0M$280.0M$295.0M$160.0M$133.0M
Cash$20.0M$13.0M$2.0M$12.0M$129.0M$131.0M$274.0M$278.0M$153.0M$124.0M
Inventory$0$1.0M$2.0M$3.0M$-129.0M$-1.0M$0$0$0$0
Receivables$0$1.0M$1.0M$0$1.0M$1.0M$0$1.0M$0$0
Fixed Assets$1.0M$2.0M$3.0M$11.0M$11.0M$9.0M$7.0M$9.0M$14.0M$9.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$20.0M$40.0M$68.0M$120.0M$68.0M$98.0M$233.0M$264.0M$47.0M$138.0M
Current Liabilities$5.0M$9.0M$16.0M$21.0M$31.0M$22.0M$28.0M$56.0M$41.0M$34.0M
Borrowings$19.0M$15.0M$9.0M$42.0M$37.0M$72.0M$207.0M$210.0M$8.0M$107.0M
Other Liabilities$1.0M$25.0M$58.0M$78.0M$31.0M$26.0M$26.0M$54.0M$39.0M$31.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$-9.0M$-29.0M$-58.0M$-94.0M$75.0M$52.0M$58.0M$44.0M$134.0M$8.0M

For Inhibrx Biosciences, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $130.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-18.0M$-19.0M$-23.0M$-32.0M$-48.0M$-80.0M$-115.0M$-193.0M$-194.0M$-130.0M
Investing Cash Flow$0$-3.0M$-3.0M$-4.0M$-3.0M$-2.0M$-1.0M$-9.0M$-5.0M$0
Financing Cash Flow$29.0M$15.0M$14.0M$43.0M$166.0M$0$129.0M$0$0$0
Net Cash Flow$10.0M$-7.0M$-11.0M$9.0M$117.0M$3.0M$143.0M$4.0M$-125.0M$-28.0M
Free Cash Flow$-18.0M$-20.0M$-25.0M$-34.0M$-49.0M$-81.0M$-116.0M$-198.0M$-197.0M$-130.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.59
EV / EBITDA-10.94
FCF Yield-9.13%
Quick Ratio5.07
Interest Coverage-8.21
Return 1Y266.38%
Return 3Y—
Return 5Y—

Inhibrx Biosciences, Inc. (INBX) financials — frequently asked questions

What is Inhibrx Biosciences, Inc.'s annual revenue?

Inhibrx Biosciences, Inc. (INBX) reported annual revenue of $1.0M in its most recent fiscal year.

What is Inhibrx Biosciences, Inc.'s net profit?

Inhibrx Biosciences, Inc. (INBX) reported a net loss of $140.0M in its most recent fiscal year.

What is INBX EV/EBITDA?

Inhibrx Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -10.94. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
INBX Overview INBX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.